Patent · US Active

Method of detecting TIM-3 using antibody molecules to TIM-3

US11155620B2 · kind B2 · utility

5Cited by

122References

20Claims

0Family size

Assignees

Novartis AG · CH
DANA-FARBER CANCER INSTITUTE, INC. · US
Children's Medical Center Corporation · US

Inventors

Catherine Anne Sabatos-Peyton · Cambridge, US
Barbara Brannetti · Basel, CH
Alan S. Harris · Andover, US
Thomas Huber · Basel, CH
Thomas Pietzonka · Basel, CH
Jennifer Marie Mataraza · Cambridge, US
Walter A. Blattler · Brookline, US
Daniel Hicklin · Montclair, US
Maximiliano Vasquez · Palo Alto, US
Rosemarie Dekruyff · Newton, US
Dale T. Umetsu · Stanford, US
Gordon J. Freeman · Brookline, US
Tiancen Hu · Cambridge, US
John A. Taraszka · Cambridge, US
Fangmin Xu · Cambridge, US

Key dates

Filing date	Sep 30, 2019
Grant date	Oct 26, 2021
Priority date	—
Expiry date	Oct 21, 2039

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.